$0.37
-4.65%
N/A-$0.02
헬스케어
생명공학
NASDAQ
활발히 거래 중
Immutep Limited는 생명공학 기업으로, 호주에서 암 및 자가면역 질환 치료를 위한 Lymphocyte Activation Gene-3(LAG-3) 관련 신규 면역치료제를 개발하고 있습니다. 주요 파이프라인 후보물질은 ...
Immutep Limited는 생명공학 기업으로, 호주에서 암 및 자가면역 질환 치료를 위한 Lymphocyte Activation Gene-3(LAG-3) 관련 신규 면역치료제를 개발하고 있습니다. 주요 파이프라인 후보물질은 ...
Eftilagimod alfa (efti) is Immutep's lead clinical-stage product candidate. It is a first-in-class soluble LAG-3 fusion protein that acts as an APC activator. By binding to MHC class II molecules, it stimulates the activation and proliferation of CD8+ T cells, which are crucial for fighting cancer. It is currently being tested in various combinations with chemotherapy and immuno-oncology agents for indications including non-small cell lung cancer, head and neck squamous cell carcinoma, and metastatic breast cancer.
가격대: N/A (Clinical-stage pharmaceutical asset)
페인 포인트: Low patient response rates to existing standard-of-care cancer therapies and the need for more effective treatments in advanced solid tumors.
솔루션: Enhances the efficacy of existing cancer therapies by boosting the patient's own immune system to recognize and eliminate tumor cells.
대상 사용자: Oncology patients with solid tumors including NSCLC, HNSCC, and metastatic breast cancer, and the healthcare providers/hospitals treating them.
IMP761 is the first clinical-stage agonist antibody targeting the LAG-3 immune checkpoint. Unlike antagonists that 'release the brakes' on the immune system, IMP761 is designed to boost LAG-3 activity, thereby dampening overactive immune responses that cause autoimmune diseases.
가격대: N/A (Clinical-stage pharmaceutical asset)
페인 포인트: The need for specific, targeted therapies that can modulate the immune system without inducing broad immunosuppression.
솔루션: Provides a targeted mechanism to restore immune homeostasis in patients suffering from autoimmune conditions.
대상 사용자: Patients suffering from various autoimmune and inflammatory diseases.
IMP731 is a depleting antibody that targets LAG-3 expressing cells. By identifying and depleting the specific T cells involved in an autoimmune attack, it aims to treat conditions such as ulcerative colitis and psoriasis without affecting the entire immune repertoire.
가격대: N/A (Clinical-stage pharmaceutical asset)
페인 포인트: The limited efficacy or severe side effects of broad-spectrum immunosuppressants in treating chronic autoimmune diseases.
솔루션: Selective depletion of pathogenic T-cells to reduce inflammation while potentially minimizing off-target immune suppression.
대상 사용자: Patients diagnosed with ulcerative colitis, psoriasis, and other related autoimmune inflammatory disorders.
LAG525 is a humanized monoclonal antibody that acts as an antagonist to LAG-3. By blocking the LAG-3 pathway, it restores T-cell function and enhances anti-tumor immunity. The global rights were licensed to Novartis, which manages its ongoing clinical development across various oncology indications.
가격대: N/A (Out-licensed asset)
페인 포인트: Tumor-induced immune evasion where cancer cells 'turn off' the immune system via the LAG-3 pathway.
솔루션: Unblocks the immune system, allowing T-cells to identify and destroy cancer cells.
대상 사용자: Oncology patients with resistant solid tumors or hematological malignancies.